Novel oral anticoagulant drugs and severe oesophagitis dissecans

2016 ◽  
Vol 46 (12) ◽  
pp. 1456-1457 ◽  
Author(s):  
R. Cox ◽  
E. Roche ◽  
S. Fairley
Keyword(s):  
Oral Anticoagulant ◽  
Anticoagulant Drugs ◽  
Novel Oral Anticoagulant

Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice

2015 ◽  
Vol 242 (2) ◽  
pp. 639-646 ◽  
Author(s):  
Tomoya Hara ◽  
Daiju Fukuda ◽  
Kimie Tanaka ◽  
Yasutomi Higashikuni ◽  
Yoichiro Hirata ◽  
...  
Keyword(s):  
Atherosclerotic Plaque ◽  
Oral Anticoagulant ◽  
Plaque Progression ◽  
Novel Oral Anticoagulant ◽  
Deficient Mice

scholarly journals P392Assessment of novel oral anticoagulant use in real-world setting: importance of a structured anticoagulation unit

EP Europace ◽  
2018 ◽  
Vol 20 (suppl_1) ◽  
pp. i70-i71
Author(s):  
A Monteiro ◽  
P Cunha ◽  
M Oliveira ◽  
M Cruz ◽  
S Aguiar ◽  
...  
Keyword(s):  
Real World ◽  
Oral Anticoagulant ◽  
Real World Setting ◽  
Novel Oral Anticoagulant

scholarly journals HAS-BLED scor system for the assessment of risk of breathing of patients on oral anticoagulant therapy // HAS-BLED skor sistem bodovanja za procjenu rizika od krvarenja pacijenata na oralnoj antikoagulantnoj terapiji

2018 ◽  
Vol 5 (1) ◽  
pp. 11
Author(s):  
Daniela Dobrovoljski
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulant ◽  
Oral Anticoagulant Therapy ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Heart Rhythm ◽  
Clinical Problem ◽  
Coagulation Factors ◽  
Heart Rhythm Disorders ◽  
Anticoagulant Drugs

Oral anticoagulant drugs (OALs) are effective agents in the prevention and treatment of thromboembolic complications. However, despite standardization and application progression, OALs represent a significant clinical problem because they are small-therapeutic medicines that easily interact with food and medicine, which can substantially affect the increased or weakened therapeutic effect. Oral anticoagulants are 4-hydroxycoumarin derivatives and vitamin K antagonists, and their pharmacological activity is based on inhibition of the synthesis of coagulation factors in the liver. These drugs are effective in the prevention of venous thromboembolism, acute myocardial infarction (AIM), heart rhythm disorders by type of atrial fibrillation, stroke prevention, and the like. The most important and clinically commonly undesirable effect of OAL is bleeding. The risk of bleeding is greatest during the introduction of the drug in therapy and for the first few months of the onset of therapy. HAS-BLED scor is a skoring system developed to estimate the 1-year risk of major bleeding in patients with atrial fibrillation and is also used for other indications.

Sign in / Sign up

Export Citation Format

Share Document